Literature DB >> 29047090

Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension.

Lydie Plecitá-Hlavatá1, Angelo D'alessandro2, Karim El Kasmi3,4, Min Li4, Hui Zhang4, Petr Ježek5, Kurt R Stenmark4.   

Abstract

Pulmonary hypertension is a complex disease of the pulmonary vasculature, which in severe cases terminates in right heart failure. Complex remodeling of pulmonary arteries comprises the central issue of its pathology. This includes extensive proliferation, apoptotic resistance and inflammation. As such, the molecular and cellular features of pulmonary hypertension resemble hallmark characteristics of cancer cell behavior. The vascular remodeling derives from significant metabolic changes in resident cells, which we describe in detail. It affects not only cells of pulmonary artery wall, but also its immediate microenvironment involving cells of immune system (i.e., macrophages). Thus aberrant metabolism constitutes principle component of the cancer-like theory of pulmonary hypertension. The metabolic changes in pulmonary artery cells resemble the cancer associated Warburg effect, involving incomplete glucose oxidation through aerobic glycolysis with depressed mitochondrial catabolism enabling the fueling of anabolic reactions with amino acids, nucleotides and lipids to sustain proliferation. Macrophages also undergo overlapping but distinct metabolic reprogramming inducing specific activation or polarization states that enable their participation in the vascular remodeling process. Such metabolic synergy drives chronic inflammation further contributing to remodeling. Enhanced glycolytic flux together with suppressed mitochondrial bioenergetics promotes the accumulation of reducing equivalents, NAD(P)H. We discuss the enzymes and reactions involved. The reducing equivalents modulate the regulation of proteins using NAD(P)H as the transcriptional co-repressor C-terminal binding protein 1 cofactor and significantly impact redox status (through GSH, NAD(P)H oxidases, etc.), which together act to control the phenotype of the cells of pulmonary arteries. The altered mitochondrial metabolism changes its redox poise, which together with enhanced NAD(P)H oxidase activity and reduced enzymatic antioxidant activity promotes a pro-oxidative cellular status. Herein we discuss all described metabolic changes along with resultant alterations in redox status, which result in excessive proliferation, apoptotic resistance, and inflammation, further leading to pulmonary arterial wall remodeling and thus establishing pulmonary artery hypertension pathology.

Entities:  

Keywords:  Aerobic glycolysis; Immune system; Mitochondrial catabolism; NAD(P)H oxidase; Pulmonary arterial wall remodeling; Pulmonary hypertension

Mesh:

Year:  2017        PMID: 29047090     DOI: 10.1007/978-3-319-63245-2_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

2.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

3.  Pharmacometabolomics Profiling of Preterm Infants Validates Patterns of Metabolism Associated With Response to Dexamethasone Treatment for Bronchopulmonary Dysplasia.

Authors:  Bradley Stockard; Cheri Gauldin; William Truog; Tamorah Lewis
Journal:  Front Pediatr       Date:  2022-06-10       Impact factor: 3.569

Review 4.  Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.

Authors:  Cheng-Jun Hu; Hui Zhang; Aya Laux; Soni S Pullamsetti; Kurt R Stenmark
Journal:  J Physiol       Date:  2018-08-07       Impact factor: 5.182

Review 5.  Redox Signaling from Mitochondria: Signal Propagation and Its Targets.

Authors:  Petr Ježek; Blanka Holendová; Lydie Plecitá-Hlavatá
Journal:  Biomolecules       Date:  2020-01-06

Review 6.  Endothelial Cell Mechano-Metabolomic Coupling to Disease States in the Lung Microvasculature.

Authors:  David Wu; Konstantin Birukov
Journal:  Front Bioeng Biotechnol       Date:  2019-07-19

7.  Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment.

Authors:  Daniel Hernandez-Saavedra; Linda Sanders; Scott Freeman; Julie A Reisz; Michael H Lee; Claudia Mickael; Rahul Kumar; Biruk Kassa; Sue Gu; Angelo D' Alessandro; Kurt R Stenmark; Rubin M Tuder; Brian B Graham
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.